Europe

Actelion board nominates two

Wednesday, April 6, 2011 12:40 PM

Actelion has nominated two pharmaceutical executives, including ex-GlaxoSmithKline boss Jean-Pierre Garnier, to join the board after shareholder Elliott Advisors repeated calls for changes in management and strategy, according to Pharma Times.

More... »

University of Leicester to build research center

Tuesday, April 5, 2011 03:02 PM

The University of Leicester is consolidating its position as one of the U.K.’s academic centers for heart disease research by building a 2,200 sq m Cardiovascular Research Centre (CRC) at the city’s Glenfield Hospital, according to Pharma Times.

More... »

Health Research Bus takes clinical trials on the road to boost recruitment, retention in U.K. cities

Monday, April 4, 2011 10:25 AM

With recruitment for clinical trials being tough and retention being even tougher, some are taking recruitment efforts and patient visits directly to the community, instead of waiting for volunteers to come to them.

More... »

University of Cambridge opens pancreatic cancer research center

Tuesday, March 29, 2011 01:09 PM

The University of Cambridge, U.K., has opened the Cambridge Pancreatic Cancer Center, a multi-disciplinary center focusing on pancreatic research.

More... »

Celerion gains membership in U.K. respiratory cluster

Tuesday, March 29, 2011 12:11 PM

CRO Celerion, which provides early-stage drug development solutions, said its Belfast facility has gained membership within the U.K. Respiratory Therapeutic Capability Cluster. Celerion will work with key decision makers in the U.K. to develop and execute phase I and IIa studies with targeted patient populations.

More... »

Clinical trials register initiated in EU

Thursday, March 24, 2011 01:42 PM

An online register giving the public access to information on clinical trials authorized in the 27 E.U. member states as well as Iceland, Liechtenstein and Norway has been launched by the EMA, according to PharmaTimes.

More... »

EMA restricts former chief’s activities

Wednesday, March 23, 2011 12:03 PM

Former EMA executive director Thomas Lonngren is facing regulatory issues regarding his plans to consult for pharma companies.

More... »

Second phase III Novartis JAK inhibitor study meets primary endpoint

Tuesday, March 22, 2011 12:08 PM

Novartis said a pivotal phase III trial of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis (MF). INC424 is a potent, selective inhibitor of the JAK1 and JAK2 tyrosine kinases.

More... »

Phlexglobal recruits research nurses for trials

Tuesday, March 22, 2011 11:52 AM

U.K.-based CRO Phlexglobal has expanded its resourcing capabilities by launching a Research Nurse Bank to supply skilled nursing staff on a temporary basis to both commercial and National Health Service clients, according to PharmaTimes.

More... »

Sativex available in Spain for MS

Thursday, March 17, 2011 01:24 PM

Almirall says Sativex is available to health professionals and patients in hospital pharmacies in Spain. It is the first specific treatment for spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other treatments. Sativex is administered as oromucosal spray enabling flexible dosage, which is particularly appropriate given the variable nature of spasticity and MS itself. It is an endocannabinoid modulator made of two actives: THC (delta-9-tetrahidrocannabinol) and CBD (cannabidiol).

More... »